Previous 10 | Next 10 |
2023-10-30 03:30:35 ET Summary Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its apparent drug effect. Biomarkers show strong reductions in patients treated with simufilam, indicating ...
2023-10-25 13:59:34 ET More on Cassava Sciences Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct Claims Cassava Sciences: Update Following Leaked CUNY Report, Fundamentals Remain Unchanged Cassava Sciences: Unconvincing Open Label Studies, Upcomin...
Safety Finding Based on Blinded MRI Brain Data at Week 40 ARIA is a Known Risk Factor for Anti-Amyloid Antibody Drugs MRI Data Presented at the 16 th CTAD Conference in Boston, MA AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: ...
ATLANTA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) complied with federal securities laws. On October 12, 2023, Science reported that, following an inv...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares are currently up 10.92% on the day to $14.02. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simuf...
2023-10-14 15:00:00 ET Weight loss drugs seen impacting container, packaging companies Weight loss drugs may lead to reduced food consumption - watch these stocks Kellanova paying attention to potential threats from weight loss meds Walmart says Oze...
2023-10-13 16:01:27 ET More on Cassava Sciences Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct Claims Cassava Sciences: Update Following Leaked CUNY Report, Fundamentals Remain Unchanged Cassava Sciences: Unconvincing Open Label Studies, Upcomin...
2023-10-13 13:05:06 ET A national policy that limited the use of a type of brain scan called positron emission tomography (PET) in testing for symptoms of Alzheimer's disease has been removed, the U.S. Centers for Medicare & Medicaid Services (CMS) said on Friday. The cause of the m...
2023-10-13 12:45:50 ET Shares of Cassava Sciences (NASDAQ: SAVA) were tanking Friday, down by almost 30% early in the session and still off by 11.6% as of 12:35 p.m. ET. The steep decline came after the company issued a public statement regarding an internal report prepared by the C...
2023-10-13 10:19:48 ET Summary Cassava Sciences faces regulatory and reputational challenges, specifically regarding allegations of scientific misconduct related to its Alzheimer's drug, simufilam. Despite a strong balance sheet, heightened R&D expenses and a complex regulator...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...